Non small cell lung cancer (NSCLC)
Conditions
Brief summary
PFS per BICR, according to RECIST v1.1
Detailed description
Overall Survival, Objective Response Rate (ORR), Duration of Response (DOR), Time to Response (TTR) per BICR and per investigator according to RECIST v1.1, PFS per investigator according to RECIST v1.1, Time to intracranial progression per BICR according to RECIST v1.1, Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to study intervention discontinuation, Drug-related AEs and deaths, Proportion of participants without meaningful symptom deterioration as measured by the NSCLC-SAQ total score
Interventions
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS per BICR, according to RECIST v1.1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, Objective Response Rate (ORR), Duration of Response (DOR), Time to Response (TTR) per BICR and per investigator according to RECIST v1.1, PFS per investigator according to RECIST v1.1, Time to intracranial progression per BICR according to RECIST v1.1, Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to study intervention discontinuation, Drug-related AEs and deaths, Proportion of participants without meaningful symptom deterioration as measured by the NSCLC-SAQ total score | — |
Countries
Austria, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Spain
Outcome results
None listed